Disruptive New Therapy

Photobiomodulation Therapy (PBM-T) is a proven, insurer-reimbursed treatment for OM, but its success has always been hindered by human variability. In light therapy, dosimetry is everything: too little is ineffective; too much is inhibitory.

By integrating patented medical device technology with machine learning algorithms, Oralight automates the administration of PBM-T.

• Operator-Independent: Precise, repeatable light dosing regardless of who is administering the treatment.

• Clinical Simplicity: A sophisticated solution designed to fit seamlessly into any clinical workflow.

• Reliable Outcomes: Ensuring every patient receives the exact therapeutic dose required for tissue regeneration.

Precision Healing: Setting a New Standard in Mucosal Care

Beyond Prevention: A Curative Vision

Oralight is currently developing a proprietary combination therapy designed to address the full pathogenesis of OM. By pairing PBM-T with a targeted antimicrobial approach, we aim to suppress microbial colonization while simultaneously accelerating healing. This next-generation therapy represents a shift from palliative care to a curative solution for advanced mucosal lesions.

For patients undergoing cancer treatment, Oral Mucositis (OM) isn't just a side effect, it’s a debilitating barrier to recovery. At Oralight, we are bridging the gap between breakthrough science and bedside reality.

The Science of Light, Perfected

Looking Ahead

In collaboration with a world-leading cancer center, we are moving toward a 2026 pilot clinical study to validate this combination approach. Our goal is simple: to ensure that no patient has to choose between life-saving treatment and their quality of life.